Marshall Wace LLP Has $3.44 Million Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Marshall Wace LLP increased its position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 1,963.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 75,849 shares of the company's stock after buying an additional 72,174 shares during the quarter. Marshall Wace LLP owned about 0.17% of Apogee Therapeutics worth $3,436,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in APGE. Affinity Asset Advisors LLC raised its position in Apogee Therapeutics by 40.3% in the fourth quarter. Affinity Asset Advisors LLC now owns 931,728 shares of the company's stock valued at $42,207,000 after purchasing an additional 267,530 shares during the period. Jump Financial LLC purchased a new position in shares of Apogee Therapeutics during the 4th quarter valued at approximately $945,000. XTX Topco Ltd purchased a new position in shares of Apogee Therapeutics during the 4th quarter valued at approximately $288,000. Barclays PLC boosted its stake in shares of Apogee Therapeutics by 30.6% during the 4th quarter. Barclays PLC now owns 476,760 shares of the company's stock valued at $21,597,000 after buying an additional 111,714 shares during the last quarter. Finally, Optimize Financial Inc purchased a new position in shares of Apogee Therapeutics during the 4th quarter valued at approximately $203,000. 79.04% of the stock is owned by hedge funds and other institutional investors.

Apogee Therapeutics Trading Up 3.8 %

NASDAQ:APGE traded up $1.42 during mid-day trading on Wednesday, reaching $39.20. 294,557 shares of the stock were exchanged, compared to its average volume of 513,140. Apogee Therapeutics, Inc. has a 1-year low of $26.20 and a 1-year high of $63.50. The firm has a market capitalization of $1.77 billion, a PE ratio of -16.20 and a beta of 1.72. The business has a fifty day moving average price of $35.30 and a 200 day moving average price of $42.48.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). On average, sell-side analysts forecast that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Insider Buying and Selling at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 3,520 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.69, for a total transaction of $143,228.80. Following the transaction, the insider now owns 252,623 shares in the company, valued at $10,279,229.87. This represents a 1.37 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael Thomas Henderson sold 10,000 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total transaction of $301,500.00. Following the transaction, the chief executive officer now owns 1,292,987 shares in the company, valued at approximately $38,983,558.05. This trade represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,970 shares of company stock worth $1,241,701. 36.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

APGE has been the topic of several research analyst reports. Citigroup initiated coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $95.00 price objective on the stock. Guggenheim restated a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $90.00 target price on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $92.17.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.